Sistemik Lupus Eritematosus’un Nöropsikiyatrik Tutulumu
Özet
Sistemik lupus eritematozus (SLE), vücudun farklı organlarını etkileyebilen kronik bir otoimmün hastalık olup nöropsikiyatrik tutulumu ciddi klinik tablolara yol açabilmektedir. Hastalığın nörolojik ve psikiyatrik belirtileri inflamasyon ve iskemi gibi patojenik mekanizmalarla ortaya çıkmakta olup, teşhis aşamasında kapsamlı klinik ve immünolojik kriterlerin değerlendirilmesi hayati önem taşır. Tedavi stratejileri, altta yatan patofizyolojiye göre belirlenerek immünsüpresif ilaçlar, antikoagülanlar ve semptomatik yöntemlerin kombinasyonunu gerektirir.
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can impact multiple organ systems, with neuropsychiatric involvement representing a critical clinical manifestation. Neurological and psychiatric symptoms arise through complex pathogenic mechanisms, including inflammation and ischemia, requiring diagnostic evaluation based on established classification criteria. Management involves personalized therapeutic strategies, combining immunosuppressive treatments, anticoagulation, and symptomatic therapy tailored to the specific underlying etiology.
Referanslar
Hochberg, MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;Sep;40(9):1725
Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86.
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Sep;71(9):1400-12.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999 Apr;42(4):599-608.
Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsänoja R, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 2001 Oct; 45(5):419-23.
Hanly JG, Kozora E, Beyea SD, Birnbaum J. Nervous system disease in systemic lupus erythematosus: Current status and future directions. Arthritis Rheumatol. 2019 Jan;71(1):33-42.
Siamopoulou-Mavridou A, Mavridis AK, Dimou G, Drosos AA. Clinical and serological spectrum of systemic lupus erythematosus in Greek children. Clin Rheumatol. 1991 Sep;10(3):264-8.
Platt JL, Burke BA, Fish AJ, Kim Y, Michael AF. Systemic lupus erythematosus in the first two decades of life. Am J Kidney Dis. 1982 Jul;2(1 Suppl 1):212-22.
Santos FPST, Nascimento BR, Calderaro DC, Ferreira GA, Correa H. Neuropsychiatric Syndromes in Childhood-Onset Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis. J Clin Rheumatol. 2021 Aug 1;27(5):206-14.
Bortoluzzi A, Scire CA, Bombardieri S, Caniatti L, Conti F, De Vita S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford). 2015 May;54(5):891-8.
Moore E, Huang MW, Putterman C. Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus. . Curr Opin Rheumatol. 2020 Mar;32(2):152-8.
Duarte-Delgado NP, Vásquez G, Ortiz-Reyes BL. Blood-brain barrier disruption and neuroinflammation as pathophysiological mechanisms of the diffuse manifestations of neuropsychiatric systemic lupus erythematosus. Autoimmun Rev. 2019 Apr;18(4):426-32.
Stock AD, Wen J, Putterman C. Neuropsychiatric Lupus, the Blood Brain Barrier, and the TWEAK/Fn14 Pathway. Front Immunol. 2013 Dec 25;4:484.
Stephan D, Sbai O, Wen J, Couraud PO, Putterman C, Khrestchatisky M, et al. J Neuroinflammation. 2013 Jan 15 ve 10:9. TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier. J Neuroinflammation. 2013 Jan 15;10:9.
Lapa AT, Postal M, Sinicato NA, Bellini BS, Fernandes PT, Marini R, et al. S100β is associated with cognitive impairment in childhood-onset systemic lupus erythematosus patients. . Lupus. 2017 Apr;26(5):478-83.
Matus S, Burgos PV, Bravo-Zehnder M, Kraft R, Porras OH, Farías P, et al. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J Exp Med. 2007 Dec 24;204(13):3221-34.
Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Clarke A, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011 Oct;70(10):1726-32.
Wen J, Stock AD, Chalmers SA, Putterman C. The role of B cells and autoantibodies in neuropsychiatric lupus. Autoimmun Rev. 2016 Sep;15(9):890-5.
Carrión-Barberà I, Salman-Monte TC, Vílchez-Oya F, Monfort J. Neuropsychiatric involvement in systemic lupus erythematosus: A review. Autoimmun Rev. 2021 Apr;20(4):102780.
Hanly JG, Urowitz MB, O'Keeffe AG, Gordon C, Bae SC, Sanchez-Guerrero J, et al. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013 Nov;65(11):2887-97. Erratum in: Arthritis Rheum. 2014 Jun;66(6):1671.
Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69:2074-82.
Kim JM, Kwok SK, Ju JH, Kim HY, Park SH. Idiopathic intracranial hypertension as a significant cause of intractable headache in patients with systemic lupus erythematosus: a 15-year experience. Lupus. 2012 Apr;21(5):542-7.
Dave S, Longmuir R, Shah VA, Wall M, Lee AG. Intracranial hypertension in systemic lupus erythematosus. Semin Ophthalmol. 2008 Mar-Apr;23(2):127-33.
Rajasekharan C, Renjith SW, Marzook A, Parvathy R. Idiopathic intracranial hypertension as the initial presentation of systemic lupus erythematosus. BMJ Case Rep. 2013 Jan 31;2013:bcr2012007886.
Devinsky O, Schein A, Najjar S. Epilepsy associated with systemic autoimmune disorders. . Epilepsy Curr. 2013 Mar;13(2):62-8.
Andrade RM, Alarcón GS, González LA, Fernández M, Apte M, Vilá LM, et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis. 2008 Jun;67(6):829-34.
Tomietto P, Annese V, D'agostini S, Venturini P, La Torre G, De Vita S, et al. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. . Arthritis Rheum. 2007 Dec 15;57(8):1461-72.
Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC ,et al. Mood disorders in systemic lupus erythematosus: results from an international inception cohort study. . Arthritis Rheumatol 2015 Jul;67(7):1837–47.
Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford). 2008 Oct;47(10):1498–502.
Shimizu Y, Yasuda S, Kako Y, Nakagawa S, Kanda M, Hisada R, et al. Post-steroid neuropsychiatric manifestations are significantly more frequent in SLE compared with other systemic autoimmune diseases and predict better prognosis compared with de novo neuropsychiatric SLE. Autoimmun Rev. 2016 Aug;15(8):786-94.
Nikolopoulos D, Fanouriakis A, Boumpas D. Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management. Mediterr J Rheumatol. 2019 Mar 28;30(1):7-15.
Ainiala H, Dastidar P, Loukkola J, Lehtimäki T, Korpela M, Peltola J, et al. Cerebral MRI abnormalities and their association with neuropsychiatric manifestations in SLE: a population-based study. Scand J Rheumatol. 2005 Sep-Oct;34(5):376-82.
Spinosa MJ, Bandeira M, Liberalesso PB, Vieira SC, Janz LL Jr, Sá EG,. Clinical, laboratory and neuroimage findings in juvenile systemic lupus erythematosus presenting involvement of the nervous system. . Arq Neuropsiquiatr. 2007 Jun;65(2B):433-9.
Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019 Oct;78(10):1296-304.
Pomper MG, Miller TJ, Stone JH, Tidmore WC, Hellmann DB. CNS vasculitis in autoimmune disease: MR imaging findings and correalation with angiography. AJNR Am J Neuroradiol. 1999 Jan;20(1):75-85.
Rodrigues M, Galego O, Costa C, Jesus D, Carvalho P, Santiago M, et al. Central nervous system vasculitis in systemic lupus erythematosus: a case series report in a tertiary referral centre. . Lupus. 2017 Nov;26(13):1440-7.
Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna). 2013 Nov;120(11):1579-89.
Hirohata S, Sakuma Y, Yanagida T, Yoshio T. Association of cerebrospinal fluid anti- Sm antibodies with acute confusional state in systemic lupus erythematosus. Arthritis Res Ther 2014 Oct2;16(5):450.
Abe G, Kikuchi H, Arinuma Y, Hirohata S. Brain MRI in patients with acute confusional state of diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Mod Rheumatol 2017 Mar;27:(2):278–83.
Widener HL, Littman BH. Ibuprofen-induced meningitis in systemic lupus erythematosus. JAMA. 1978 Mar 13;239(11):1062-4.
Baizabal-Carvallo JF, Delgadillo-Márquez G, Estañol B, García-Ramos G. Clinical characteristics and outcomes of the meningitides in systemic lupus erythematosus. Eur Neurol. 2009;61(3):143–8.
Piga M, Chessa E, Peltz MT, Floris A, Mathieu A, Cauli A. Demyelinating syndrome in SLE encompasses different subtypes: Do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmun Rev. 2017 Mar;16(3):244-252.
Chessa E, Piga M, Floris A, Mathieu A, Cauli A. Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series. Reumatismo. 2017 Dec 21;69(4):175-83.
Mader S, Jeganathan V, Arinuma Y, Fujieda Y, Dujmovic I, Drulovic J. et al. Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets? Arthritis Rheumatol. 2018 Feb;70(2):277-86.
Magro Checa C, Cohen D, Bollen EL, van Buchem MA, Huizinga TW, Steup-Beekman GM. Demyelinating disease in SLE: is it multiple sclerosis or lupus? Best Pract Res Clin Rheumatol. 2013 Jun;27(3):405-24.
Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial. 2003 Apr;7(2):173-82.
Narváez J, Ríos-Rodriguez V, de la Fuente D, Estrada P, López-Vives L, Gómez-Vaquero C, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011 Dec;41(3):364-72.
Wang L, Chen H, Zhang Y, Liu W, Zheng W, Zhang X, et al. Clinical Characteristics of Cerebral Venous Sinus Thrombosis in Patients with Systemic Lupus Erythematosus: A Single-Centre Experience in China. J Immunol Res. 2015;2015:540738. .
Deng J, Li C, Kuang W, Han T, Zhang J, Tan X, et al. Clinical characteristics of cerebral venous sinus thrombosis in childhood-onset systemic lupus erythematosus patients: a single-centre study from China. Clin Exp Rheumatol. 2021 May 5. Epub ahead of print. PMID: 34001299.
Cui HW, Lei RY, Zhang SG, Han LS, Zhang BA. Clinical features, outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a case-control study. Lupus. 2019 Jul;28(8):961-9.
Valdez-López M, Aguirre-Aguilar E, Valdés-Ferrer SI, Martínez-Carrillo FM, Arauz A, Barrera-Vargas A, et al. Posterior reversible encephalopathy syndrome: A neuropsychiatric manifestation of systemic lupus erythematosus. Autoimmun Rev. 2021 Feb;20(2):102739.
Merayo-Chalico J, Apodaca E, Barrera-Vargas A, Alcocer-Varela J, Colunga-Pedraza I, González-Patiño A, et al. Clinical outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a multicentric case-control study. J Neurol Neurosurg Psychiatry. 2016 Mar;87(3):287-94.
McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, et al. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. JAMA Netw Open. 2021 Feb 1;4(2):e2036321.
Henegar CE, Eudy AM, Kharat V, Hill DD, Bennett D, Haight B. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus. 2016 May;25(6):617-26.
Kapoor T, Mahadeshwar P, Hui-Yuen J, Quinnies K, Tatonetti N, Gartshteyn Y, et al. Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus. Lupus Sci Med. 2020 Jun;7(1):e000388.
Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev. 2008 Dec;8(2):144-6.
Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013 Apr 9;80(15):1430-8.
Law LY, Tan I, Prowse M, Sean Riminton D, Reddel SW. Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus: Clues to early diagnosis. J Clin Neurosci. 2019 Sep;67:261-3.
Bortoluzzi A, Silvagni E, Furini F, Piga M, Govoni M. Peripheral nervous system involvement in systemic lupus erythematosus: a review of the evidence. Clin Exp Rheumatol. 2019 Jan-Feb;37(1):146-55.
Toledano P, Orueta R, Rodríguez-Pintó I, Valls-Solé J, Cervera R, Espinosa G. Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. Autoimmun Rev. 2017 Jul;16(7):750-5.
Bortoluzzi A, Piga M, Silvagni E, Chessa E, Mathieu A, Govoni M. Peripheral nervous system involvement in systemic lupus erythematosus: a retrospective study on prevalence, associated factors and outcome. Lupus. 2019 Apr;28(4):465-74.
Rivière E, Cohen Aubart F, Maisonobe T, Maurier F, Richez C, Gombert B, et al. Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study. J Neurol. 2017 Jun;264(6):1218-26.
Williams JN, Speyer CB, Kreps DJ, Kimbrough DJ, Costenbader K, Bhattacharyya S. et al. Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. Lupus. 2019 Dec;28(14):1656-62.
Saison J, Costedoat-Chalumeau N, Maucort-Boulch D, Iwaz J, Marignier R, Cacoub P, et al. Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. Lupus. 2015 Jan;24(1):74-81.
Khajezadeh MA, Zamani G, Moazzami B, Nagahi Z, Mousavi-Torshizi M, Ziaee V. Neuropsychiatric Involvement in Juvenile-Onset Systemic Lupus Erythematosus. Neurol Res Int. 2018 May 29;2018:2548142.
Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, et al. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2020 Jan;72(1):67-77.
Islabão AG, Mota LMH, Ribeiro MCM, Arabi TM, Cividatti GN, Queiroz LB, et al. Childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome: A multicenter study with 1519 patients. Autoimmun Rev. 2020 Dec;19(12):102693.
Julio PR, Cortês MMM, Costallat LTL, Gaino JZ, França MC Jr, Appenzeller S. Chronic inflammatory demyelinating polyradiculoneuropathy associated with systemic lupus erythematosus. Semin Arthritis Rheum. 2021 Feb;51(1):158-65.
Shalimar, Handa R, Deepak KK, Bhatia M, Aggarwal P, Pandey RM. Autonomic dysfunction in systemic lupus erythematosus. Rheumatol Int. 2006 Jul;26(9):837-40.
Başaran Ö, Çetin İİ, Aydın F, Uncu N, Çakar N, Ekici F, et al. Heart rate variability in juvenile systemic lupus erythematosus patients. Turk J Pediatr. 2019;61(5):733-40.
Haghighat S, Fatemi A, Andalib S. The autonomic dysfunction in patients with lupus disease: An electrophysiological study. Adv Biomed Res. 2016 Jun 8;5:102.
Jallouli M, Saadoun D, Eymard B, Leroux G, Haroche J, Le Thi Huong D, et al. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J Neurol. 2012 Jul;259(7):1290-7.
Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol. 2016 Aug;263(8):1473-94.
Oomatia A, Fang H, Petri M, Birnbaum J. Peripheral neuropathies in systemic lupus erythematosus: clinical features, disease associations, and immunologic characteristics evaluated over a twenty-five-year study period. Arthritis Rheumatol. 2014 Apr;66(4):1000-9.
Groot N, de Graeff N, Avcin T, Bader-Meunier B, Brogan P, Dolezalova P, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017 Nov;76(11):1788-96.
Olfat MO, Al-Mayouf SM, Muzaffer MA. Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clin Rheumatol. 2004 Oct;23(5):395-9.
Avcin T, Benseler SM, Tyrrell PN, Cucnik S, Silverman ED. A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum. 2008 Feb 15;59(2):206-13.
Sanna G, Piga M, Terryberry JW, Peltz MT, Giagheddu S, Satta L, et al. Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus. 2000;9(8):573-83.
Al-Obaidi M, Saunders D, Brown S, Ramsden L, Martin N, Moraitis E, et al. Evaluation of magnetic resonance imaging abnormalities in juvenile onset neuropsychiatric systemic lupus erythematosus. Clin Rheumatol. 2016 Oct;35(10):2449-56.
Coban O, Bahar S, Akman-Demir G, Taşci B, Yurdakul S, Yazici H, et al. Masked assessment of MRI findings: is it possible to differentiate neuro-Behçet's disease from other central nervous system diseases? Neuroradiology. 1999 Apr;41(4):255-60.
Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum. 2008 Mar;58(3):843-53.
Omdal R, Brokstad K, Waterloo K, Koldingsnes W, Jonsson R, Mellgren SI. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol. 2005 May;12(5):392-8.
Stojanovich L, Stojanovich R, Kostich V, Dzjolich E. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus. 2003;12(1):3-7.
Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limón JM, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005 Apr;64(4):620-5.
Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, et al. A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response. Lupus. 1999;8(9):705-12.
Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007 Apr;66(4):470-5.
Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007 Dec 15;57(8):1487-95.
Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman B, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017 Oct;76(10):1637-41.
Heinlein AC, Gertner E. Marked inflammation in catastrophic longitudinal myelitis associated with systemic lupus erythematosus. Lupus. 2007;16(10):823-6.
Klein-Gitelman MS, Beresford MW. Systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease. In:Petty RE, Laxer RM, Lindsley CB, Wedderburn L, Fuhlbrigge R, Mellins E. eds. Textbook of Pediatric Rheumatology, 8th Edition, Philadelphia, Elsevier; 2021, pp 295-325.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306.
Rodrigues CE, Carvalho JF, Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest. 2010 Apr;40(4):350-9.
Muscal E, Brey RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus. 2010 Apr;19(4):406-11.
Dale RC, Yin K, Ding A, Merheb V, Varadkhar S, McKay D, et al. Antibody binding to neuronal surface in movement disorders associated with lupus and antiphospholipid antibodies. Dev Med Child Neurol. 2011 Jun;53(6):522-8.
Levy DM, Ardoin SP, Schanberg LE. Neurocognitive impairment in children and adolescents with systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2009 Feb;5(2):106-14.
Uthman I, Noureldine MHA, Ruiz-Irastorza G, Khamashta M. Management of antiphospholipid syndrome. Ann Rheum Dis. 2019 Feb;78(2):155-61.
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010 Jan;69(1):20-8.
Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl U, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e737S-e801S.
Silverman E, Jaeggi E, Barsalou J. Neonatal lupus erythematosus. In:Petty RE, Laxer RM, Lindsley CB, Wedderburn L, Fuhlbrigge R, Mellins E. eds. Textbook of Pediatric Rheumatology, 8th Edition, Philadelphia, Elsevier; 2021, pp 346-59.
Heelan K, Watson R, Collins SM. Neonatal lupus syndrome associated with ribonucleoprotein antibodies. Pediatr Dermatol. 2013 Jul-Aug;30(4):416-23.
Chen CC, Lin KL, Chen CL, Wong AM, Huang JL. Central nervous system manifestations of neonatal lupus: a systematic review. Lupus. 2013 Dec;22(14):1484-8.
Boros CA, Spence D, Blaser S, Silverman ED. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum. 2007 Mar 15;57(2):261-6.
Wang D, Chan EK. 17-beta-estradiol increases expression of 52-kDa and 60-kDa SS-A/Ro autoantigens in human keratinocytes and breast cancer cell line MCF-7. J Invest Dermatol. 1996 Oct;107(4):610-4.
Shusta EV, Li JY, Boado RJ, Pardridge WM. The Ro52/SS-A autoantigen has elevated expression at the brain microvasculature. Neuroreport. 2003 Oct 6;14(14):1861-5.
